<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03861377</url>
  </required_header>
  <id_info>
    <org_study_id>2019/376</org_study_id>
    <secondary_id>2019-000961-19</secondary_id>
    <nct_id>NCT03861377</nct_id>
  </id_info>
  <brief_title>Hemodynamics During Induction of General Anesthesia With Medium or Low Remifentanil Doses.</brief_title>
  <acronym>RH</acronym>
  <official_title>&quot;Hemodynamic Stability During Induction of General Anesthesia With Propofol and Remifentanil: A Randomized, Controlled, Double-blind Study Comparing Medium and Low Remifentanil Doses.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helse Fonna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Helse Fonna</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this trial the investigators want to examine if there is any difference in hemodynamic
      stability during induction when comparing two low and a medium remifentanil dose and keeping
      propofol induction dose at about 2.0 mg/kg.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Typically, one or more adjuvant medications is administered during induction of general
      anesthesia. When anesthetic drugs are combined, the hypnotic effects are often synergistic.
      Propofol is associated with hypotension and bradycardia and used together with remifentanil
      or sedative agents it may give synergistic or additive sedative and hemodynamic effects.

      Remifentanil is infused at 0.05-0.3 microg/kg/min during induction of anesthesia. Some use a
      loading dose of 0.5-1.0 microg/kg before starting the continuous infusion. The onset of
      action of remifentanil is within one to two minutes and it reaches rapidly a steady state
      effect site concentration after a bolus dose.

      Kazmaier (2000) showed that a high-dose remifentanil anesthesia (2 microg/kg/min) reduced
      cardiac index (-25%), stroke volume (-14%) and mean arterial blood pressure (-39%) in a
      similar manner as propofol/remifentanil (propofol target 2 microg/ml and remifentanil 0.5
      microg/kg/min), but systemic vascular resistance index decreased (-14%) in
      propofol/remifentanil combination. Fairfield et al have earlier (1991) showed that propofol
      2.5 mg/kg induction without opioid reduces cardiac output (-15%) stroke volume (-5 %), mean
      arterial pressure (-33%) and systemic vascular resistance (-11%) and a slight reduction i
      heart rate. Guarracino (2003) suggests the reduction in cardiac index during induction with
      propofol/remifentanil with a low propofol target (1.2 microg/ml) may be due to decreased
      heart rate. Zaballos (2009) have shown that remifentanil depresses sinus node and
      atrioventricular (AV) -nodal function in comparison with propofol alone in a closed chest
      porcine model. Hayashi (2016) states that even in a low remifentanil effect site
      concentration (3.5 nanog/ml) it may reduce heart rate significantly when combined with
      propofol bolus 30-50 mg.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 9, 2020</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, controlled, double blind.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Randomization made by a person not involved in trial in other ways. Allocation masked in sealed envelopes, stored in a locked cash box only opened by two drug preparing nurses not involved in patient care. Syringe labelled with patient identification (ID) (eg 03Remi). Patient, Care Provider and Investigator blinded for actual concentration of drug. Allocation break after data data wash and processing.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Systolic Blood Pressure (SBP)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in systolic blood pressure during induction</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Heart Rate (HR)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in heart rate during induction</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Stroke Volume (SV)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in stroke volume during induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac Output (CO)</measure>
    <time_frame>First 7,5 minutes from a start of induction</time_frame>
    <description>Change in cardiac output during induction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Systemic Vascular Resistance (SVR)</measure>
    <time_frame>First 7,5 minutes from start of induction</time_frame>
    <description>Change in systemic vascular resistance during induction</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Hemodynamic Instability</condition>
  <condition>Anesthesia, General</condition>
  <condition>Anesthesia, Intravenous</condition>
  <arm_group>
    <arm_group_label>Remifentanil R2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose Remifentanil induction dose (R2)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil R4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium dose Remifentanil induction dose (R4)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Remifentanil R8</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium dose Remifentanil induction dose (R8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil R2</intervention_name>
    <description>0,7 microg/kg</description>
    <arm_group_label>Remifentanil R2</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil R4</intervention_name>
    <description>1,1 microg/kg</description>
    <arm_group_label>Remifentanil R4</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Remifentanil R8</intervention_name>
    <description>1,7 microg/kg</description>
    <arm_group_label>Remifentanil R8</arm_group_label>
    <other_name>Ultiva</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Gynecological procedure

          -  Age 18-50 years

          -  General anesthesia planned

          -  Systolic blood pressure &lt; 150 mmHg, HR &lt; 100 beats/min

        Exclusion Criteria:

          -  Pre-existing hypertension

          -  Diabetes

          -  Ischemic heart disease or cerebrovascular disease

          -  Heart valve disease

          -  Verified cardiac arrhythmia other than extrasystoles

          -  Verified anaemia with hemoglobin level below 9.0 gr/dl.

          -  Kidney or hepatic disease

          -  Hypersensitivity for propofol, soya, eggs or peanuts

          -  Pregnancy

          -  Poor health state

          -  Illicit substance use

          -  BMI &lt;20 or &gt;35 kg/m2
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Sjøen, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helse Fonna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Haldis Økland Lier</last_name>
    <phone>004752732000</phone>
    <email>haldis.johanne.okland.lier@helse-fonna.no</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Berit Haaland</last_name>
    <phone>004752732602</phone>
    <email>Berit.Haaland@helse-fonna.no</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Kirurgisk Klinikk Anestesi</name>
      <address>
        <city>Haugesund</city>
        <state>Rogaland</state>
        <zip>5504</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Haldis Økland, PhD</last_name>
      <phone>52732000</phone>
      <phone_ext>0047</phone_ext>
      <email>haldis.okland.lier@helse-fonna.no</email>
    </contact>
    <contact_backup>
      <last_name>Gunnar Sjøen, MD</last_name>
      <phone>52732000</phone>
      <phone_ext>0047</phone_ext>
      <email>gunnar.helge.sjoeen@helse-fonna.no</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <reference>
    <citation>Kazmaier S, Hanekop GG, Buhre W, Weyland A, Busch T, Radke OC, Zoelffel R, Sonntag H. Myocardial consequences of remifentanil in patients with coronary artery disease. Br J Anaesth. 2000 May;84(5):578-83.</citation>
    <PMID>10844832</PMID>
  </reference>
  <reference>
    <citation>Fairfield JE, Dritsas A, Beale RJ. Haemodynamic effects of propofol: induction with 2.5 mg kg-1. Br J Anaesth. 1991 Nov;67(5):618-20.</citation>
    <PMID>1751277</PMID>
  </reference>
  <reference>
    <citation>Guarracino F, Penzo D, De Cosmo D, Vardanega A, De Stefani R. Pharmacokinetic-based total intravenous anaesthesia using remifentanil and propofol for surgical myocardial revascularization. Eur J Anaesthesiol. 2003 May;20(5):385-90.</citation>
    <PMID>12790210</PMID>
  </reference>
  <reference>
    <citation>Zaballos M, Jimeno C, Almendral J, Atienza F, Patiño D, Valdes E, Navia J, Anadón MJ. Cardiac electrophysiological effects of remifentanil: study in a closed-chest porcine model. Br J Anaesth. 2009 Aug;103(2):191-8. doi: 10.1093/bja/aep131. Epub 2009 May 20.</citation>
    <PMID>19457895</PMID>
  </reference>
  <reference>
    <citation>Hayashi K, Tanaka A. Effect-site concentrations of remifentanil causing bradycardia in hypnotic and non-hypnotic patients. J Clin Monit Comput. 2016 Dec;30(6):919-924. Epub 2015 Oct 13.</citation>
    <PMID>26462495</PMID>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>March 1, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 4, 2019</study_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Helse Fonna</investigator_affiliation>
    <investigator_full_name>Gunnar Helge Sjøen</investigator_full_name>
    <investigator_title>Consultant in Anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Cardiac Output (CO)</keyword>
  <keyword>Systolic Blood Pressure (SBP)</keyword>
  <keyword>Systemic Vascular Resistance (SVR)</keyword>
  <keyword>Heart Rate (HR)</keyword>
  <keyword>Stroke Volume (SV)</keyword>
  <keyword>Lithium Dilutional Cardiac Output (LiDCO)</keyword>
  <keyword>Minimal Invasive Hemodynamic Monitor</keyword>
  <keyword>Remifentanil</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>LiDCO-csv raw data and processed data will be made public at the publishers site, and the supporting information by request to the Principal Investigator. Statistical Data Plan is included in Study Protocol.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The data will be stored for 15 years after end of study, and may be shared during this time frame.</ipd_time_frame>
    <ipd_access_criteria>The data may be shared by contacting the Principal Investigator.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

